GlassScriptPhysician profile
Jim M Ingram
NPI 1093707176
$62,346.65
in general payments reported to CMS, 2019-2025
33 companies · $2,407 in 2025
The $2,407 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $7,373 · 2021: $17K · 2022: $1,715 · 2023: $1,726 · 2024: $1,669 · 2025: $2,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,740 · Consulting Fee: $39.93 · Education: $22.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,739.75 |
| Consulting Fee | $39.93 |
| Education | $22.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $30,078.68 | 2019-2025 | Dupixent |
| Genzyme Corporation | $21,732.14 | 2019-2025 | |
| Pfizer INC. | $2,360.19 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,909.38 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,892.52 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $764.30 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Grifols USA, LLC | $632.92 | 2019-2025 | Xembify |
| Novartis Pharmaceuticals Corporation | $535.70 | 2019-2025 | |
| Genentech USA, INC. | $461.10 | 2019-2025 | Xolair |
| Kaleo, INC. | $341.94 | 2019-2023 | Auvi-Q |
| Amgen INC. | $242.41 | 2021-2025 | Tezspire |
| Octapharma USA, INC. | $239.48 | 2019-2020 | |
| Ars Pharmaceuticals Operations, INC. | $174.00 | 2025 | Neffy |
| Leo Pharma INC. | $158.80 | 2022-2025 | Adbry, Anzupgo |
| Optinose US, INC. | $153.26 | 2019-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $99.39 | 2024-2025 | Ebglyss, Taltz |
| Takeda Pharmaceuticals U.S.A., INC. | $81.33 | 2020-2024 | Eohilia |
| Biocryst US Sales Co., LLC | $76.28 | 2023-2025 | Orladeyo |
| Hikma Pharmaceuticals USA | $56.93 | 2023-2024 | Ryaltris |
| Adma Biomanufacturing LLC | $53.15 | 2021-2025 | |
| Shire North American Group INC | $48.65 | 2019 | |
| Mylan Specialty L.P. | $39.18 | 2019-2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $27.60 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.24 | 2020-2022 | |
| Pharming Healthcare, INC. | $23.72 | 2024 | Ruconest |
| Gc Biopharma USA, INC. | $20.17 | 2025 | Alyglo |
| Uswm, LLC | $20.00 | 2021 | |
| Alk-Abello, INC | $18.90 | 2023 | Grastek, Ragwitek, Odactra |
| Arcutis Biotherapeutics, INC. | $18.08 | 2025 | Zoryve |
| Ionis Pharmaceuticals, INC. | $16.76 | 2025 | Dawnzera |
| Kedrion Biopharma, INC. | $16.08 | 2024 | Rhogam Ultra-Filtered Plus, Kedrab, Albuked |
| Merck Sharp & Dohme LLC | $15.76 | 2023 | |
| Greer Laboratories, INC. | $13.61 | 2024 | Palforzia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jim Ingram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.